Artificial Intelligence, Real-World Automation and the Safety of Medicines.
Journal
Drug safety
ISSN: 1179-1942
Titre abrégé: Drug Saf
Pays: New Zealand
ID NLM: 9002928
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
accepted:
08
09
2020
pubmed:
8
10
2020
medline:
10
2
2022
entrez:
7
10
2020
Statut:
ppublish
Résumé
Despite huge technological advances in the capabilities to capture, store, link and analyse data electronically, there has been some but limited impact on routine pharmacovigilance. We discuss emerging research in the use of artificial intelligence, machine learning and automation across the pharmacovigilance lifecycle including pre-licensure. Reasons are provided on why adoption is challenging and we also provide a perspective on changes needed to accelerate adoption, and thereby improve patient safety. Last, we make clear that while technologies could be superimposed on existing pharmacovigilance processes for incremental improvements, these great societal advances in data and technology also provide us with a timely opportunity to reconsider everything we do in pharmacovigilance operations to maximise the benefit of these advances.
Identifiants
pubmed: 33026641
doi: 10.1007/s40264-020-01001-7
pii: 10.1007/s40264-020-01001-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
125-132Références
Crown WH. Real-world evidence, causal inference, and machine learning. Value Health. 2019;22(5):587–92.
pubmed: 31104739
Inman WH. Monitoring of adverse reactions to drugs in the United Kingdom. Proc R Soc Med. 1970;63(12):1302–4.
pubmed: 5490790
pmcid: 1812375
Jick H, Miettinen OS, Shapiro S, Lewis GP, Siskind V, Slone D. Comprehensive drug surveillance. JAMA. 1970;213(9):1455–60.
pubmed: 5468449
Finney DJ. Systemic signalling of adverse reactions to drugs. Methods Inf Med. 1974;13(1):1–10.
pubmed: 4826353
Levine A, Mandel SP, Santamaria A. Pattern signalling in health information monitoring systems. Methods Inf Med. 1977;16(3):138–44.
pubmed: 904476
Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427–36.
pubmed: 19358225
Hauben M, Noren GN. A decade of data mining and still counting. Drug Saf. 2010;33(7):527–34.
pubmed: 20553054
Bate A, Reynolds RF, Caubel P. The hope, hype and reality of Big Data for pharmacovigilance. Ther Adv Drug Saf. 2018;9(1):5–11.
pubmed: 29318002
Hand DJ. Artificial intelligence and medicine: discussion paper. J R Soc Med. 1987;80(9):563–5.
pubmed: 3316650
pmcid: 1291001
Barr A, Feigenbaum EA. The handbook of artificial intelligence. Los Altos: William Kaufmann, Inc.; 1981.
Das S, Dey A, Pal A, Roy N. Applications of artificial intelligence in machine learning: review and prospect. Int J Comp Appl. 2015;115(9):31–41.
Berkan RC, Upadhyaya BR, Tsoukalas LH, Kisner RA, Bywater RL. Advanced automation concepts for large-scale systems. IEEE Control Syst Mag. 1991;11(6):4–12.
Ting DSW, Cheung CY, Lim G, Tan GSW, Quang ND, Gan A, et al. Development and validation of a deep learning system for diabetic retinopathy and related eye diseases using retinal images from multiethnic populations with diabetes. JAMA. 2017;318(22):2211–23.
pubmed: 29234807
pmcid: 5820739
Akselrod-Ballin A, Chorev M, Shoshan Y, Spiro A, Hazan A, Melamed R, et al. Predicting breast cancer by applying deep learning to linked health records and mammograms. Radiology. 2019;292(2):331–42.
pubmed: 31210611
Finkelstein J, Wood J. Predicting asthma exacerbations using artificial intelligence. Stud Health Technol Inform. 2013;190:56–8.
pubmed: 23823374
Curran K, Nichols E, Xie E, Harper R. An intensive insulinotherapy mobile phone application built on artificial intelligence techniques. J Diabetes Sci Technol. 2010;4(1):209–20.
pubmed: 20167186
pmcid: 2825643
Cruz AS, Lins HC, Medeiros RVA, Filho JMF, da Silva SG. Artificial intelligence on the identification of risk groups for osteoporosis, a general review. Biomed Eng Online. 2018;17(1):12.
pubmed: 29378578
pmcid: 5789692
Labovitz DL, Shafner L, Reyes Gil M, Virmani D, Hanina A. Using artificial intelligence to reduce the risk of nonadherence in patients on anticoagulation therapy. Stroke. 2017;48(5):1416–9.
pubmed: 28386037
pmcid: 5432369
Doshi R, Falzon D, Thomas BV, Temesgen Z, Sadasivan L, Migliori GB, et al. Tuberculosis control, and the where and why of artificial intelligence. ERJ Open Res. 2017;3(2):00056–2017.
pubmed: 28656130
pmcid: 5478795
Anumanchipalli GK, Chartier J, Chang EF. Speech synthesis from neural decoding of spoken sentences. Nature. 2019;568(7753):493–8.
pubmed: 31019317
Fiore LD, Lavori PW. Integrating randomized comparative effectiveness research with patient care. N Engl J Med. 2016;374(22):2152–8.
pubmed: 27248620
Persson M, Hornberg JJ. Advances in predictive toxicology for discovery safety through high content screening. Chem Res Toxicol. 2016;29(12):1998–2007.
pubmed: 27766849
Luechtefeld T, Marsh D, Rowlands C, Hartung T. Machine learning of toxicological Big Data enables read-across structure activity relationships (RASAR) outperforming animal test reproducibility. Toxicol Sci. 2018;165(1):198–212.
pubmed: 30007363
pmcid: 6135638
Alvager T, Smith TJ, Vijai F. Neural-network applications for analysis of adverse drug reactions. Biomed Instrum Technol. 1993;27(5):408–11.
pubmed: 8220635
Edwards IR. Adverse drug reactions: finding the needle in the haystack. BMJ. 1997;315(7107):500.
pubmed: 9329298
pmcid: 2127377
Ghosh R, Kempf D, Pufko A, Barrios Martinez LF, Davis CM, Sethi S. Automation opportunities in pharmacovigilance: an industry survey. Pharm Med. 2020;34(1):7–18.
Comfort S, Perera S, Hudson Z, Dorrell D, Meireis S, Nagarajan M, et al. Sorting through the safety data haystack: using machine learning to identify individual case safety reports in social-digital media. Drug Saf. 2018;41(6):579–90.
pubmed: 29446035
pmcid: 5966485
Schmider J, Kumar K, LaForest C, Swankoski B, Naim K, Caubel PM. Innovation in pharmacovigilance: use of artificial intelligence in adverse event case processing. Clin Pharmacol Ther. 2019;105(4):954–61.
pubmed: 30303528
Routray R, Tetarenko N, Abu-Assal C, Mockute R, Assuncao B, Chen H, et al. Application of augmented intelligence for pharmacovigilance case seriousness determination. Drug Saf. 2020;43(1):57–66.
pubmed: 31605285
Han L, Ball R, Pamer CA, Altman RB, Proestel S. Development of an automated assessment tool for MedWatch reports in the FDA adverse event reporting system. J Am Med Inform Assoc. 2017;24(5):913–20.
pubmed: 28371826
pmcid: 7651970
Chandler RE, Juhlin K, Fransson J, Caster O, Edwards IR, Noren GN. Current safety concerns with human papillomavirus vaccine: a cluster analysis of reports in VigiBase
pubmed: 27638661
Orre R, Bate A, Noren GN, Swahn E, Arnborg S, Edwards IR. A Bayesian recurrent neural network for unsupervised pattern recognition in large incomplete data sets. Int J Neural Syst. 2005;15(3):207–22.
pubmed: 16013091
Whalen E, Hauben M, Bate A. Time series disturbance detection for hypothesis-free signal detection in longitudinal observational databases. Drug Saf. 2018;41(6):565–77.
pubmed: 29468602
Vanderwall DE, Yuen N, Al-Ansari M, Bailey J, Fram D, Green DV, et al. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery: the GSK experience. Drug Discov Today. 2011;16(15–16):646–53.
pubmed: 21601652
Nikfarjam A, Sarker A, O’Connor K, Ginn R, Gonzalez G. Pharmacovigilance from social media: mining adverse drug reaction mentions using sequence labeling with word embedding cluster features. J Am Med Inform Assoc. 2015;22(3):671–81.
pubmed: 25755127
pmcid: 4457113
van Stekelenborg J, Ellenius J, Maskell S, Bergvall T, Caster O, Dasgupta N, et al. Recommendations for the use of social media in pharmacovigilance: lessons from IMI WEB-RADR. Drug Saf. 2019;42(12):1393–407.
pubmed: 31446567
pmcid: 6858385
Strandell J, Caster O, Bate A, Noren N, Edwards IR. Reporting patterns indicative of adverse drug interactions: a systematic evaluation in VigiBase. Drug Saf. 2011;34(3):253–66.
pubmed: 21332249
Ly T, Pamer C, Dang O, Brajovic S, Haider S, Botsis T, et al. Evaluation of natural language processing (NLP) systems to annotate drug product labeling with MedDRA terminology. J Biomed Inform. 2018;83:73–86.
pubmed: 29860093
Wang W, Haerian K, Salmasian H, Harpaz R, Chase H, Friedman C. A drug-adverse event extraction algorithm to support pharmacovigilance knowledge mining from PubMed citations. In: American medical informatics association annual symposium proceedings; 2011. p. 1464.
Walker AM, Zhou X, Ananthakrishnan AN, Weiss LS, Shen R, Sobel RE, et al. Computer-assisted expert case definition in electronic health records. Int J Med Inform. 2016;86:62–70.
pubmed: 26725697
Weiss LS, Zhou X, Walker AM, Ananthakrishnan AN, Shen R, Sobel RE, et al. A case study of the incremental utility for disease identification of natural language processing in electronic medical records. Pharm Med. 2018;32(1):31–7.
Luo Y, Thompson WK, Herr TM, Zeng Z, Berendsen MA, Jonnalagadda SR, et al. Natural language processing for EHR-based pharmacovigilance: a structured review. Drug Saf. 2017;40(11):1075–89.
pubmed: 28643174
Bate A, Brown EG, Goldman SA, Hauben M. Terminological challenges in safety surveillance. Drug Saf. 2012;35(1):79–84.
pubmed: 22136184
Gattepaille LM. Using the WHO database of spontaneous reports to build joint vector representations of drugs and adverse drug reactions, a promising avenue for pharmacovigilance. In: 2019 IEEE international conference on healthcare informatics (ICHI); 2019. p. 1–6.
Wong J, Horwitz MM, Zhou L, Toh S. Using machine learning to identify health outcomes from electronic health record data. Curr Epidemiol Rep. 2018;5(4):331–42.
pubmed: 30555773
pmcid: 6289196
Park MY, Yoon D, Choi NK, Lee J, Lee K, Lim HS, et al. Construction of an open-access QT database for detecting the proarrhythmia potential of marketed drugs: ECG-ViEW. Clin Pharmacol Ther. 2012;92(3):393–6.
pubmed: 22828716
Orriols L, Delorme B, Gadegbeku B, Tricotel A, Contrand B, Laumon B, et al. Prescription medicines and the risk of road traffic crashes: a French registry-based study. PLoS Med. 2010;7(11):e1000366.
pubmed: 21125020
pmcid: 2981588
Bolaños M, Garolera M, Radeva P. Active labeling application applied to food-related object recognition. In: Proceedings of the 5th international workshop on multimedia for cooking and eating activities; 2013: p. 45–50.
Schneeweiss S. Automated data-adaptive analytics for electronic healthcare data to study causal treatment effects. Clin Epidemiol. 2018;10:771.
pubmed: 30013400
pmcid: 6039060
Schuler MS, Rose S. Targeted maximum likelihood estimation for causal inference in observational studies. Am J Epidemiol. 2017;185(1):65–73.
pubmed: 27941068
Hernán MA, Hsu J, Healy B. A second chance to get causal inference right: a classification of data science tasks. Chance. 2019;32(1):42–9.
Norén GN, Orre R, Bate A, Edwards IR. Duplicate detection in adverse drug reaction surveillance. Data Min Knowl Discov. 2007;14(3):305–28.
Koutkias VG, Lillo-Le Louet A, Jaulent MC. Exploiting heterogeneous publicly available data sources for drug safety surveillance: computational framework and case studies. Expert Opin Drug Saf. 2017;16(2):113–24.
pubmed: 27813420
Rajkomar A, Oren E, Chen K, Dai AM, Hajaj N, Hardt M, et al. Scalable and accurate deep learning with electronic health records. NPJ Digit Med. 2018;1:18.
pubmed: 31304302
pmcid: 6550175
Lasko TA, Denny JC, Levy MA. Computational phenotype discovery using unsupervised feature learning over noisy, sparse, and irregular clinical data. PLoS One. 2013;8(6):e66341.
pubmed: 23826094
pmcid: 3691199
Weissenbacher D, Sarker A, Klein A, O’Connor K, Magge A, Gonzalez-Hernandez G. Deep neural networks ensemble for detecting medication mentions in tweets. J Am Med Inform Assoc. 2019;26(12):1618–26.
pubmed: 31562510
pmcid: 6857507
Wang CS, Lin PJ, Cheng CL, Tai SH, Kao Yang YH, Chiang JH. Detecting potential adverse drug reactions using a deep neural network model. J Med Internet Res. 2019;21(2):e11016.
pubmed: 30724742
pmcid: 6381404
Hinton G, Vinyals O, Dean J. Distilling the knowledge in a neural network. 2015. arXiv preprint. arXiv:150302531 .
Ferner R, Aronson J. Susceptibility to adverse drug reactions. Br J Clin Pharmacol. 2019;85(10):2205–12.
pubmed: 31169324
pmcid: 6783620
Bate A, Edwards IR. Data mining techniques in pharmacovigilance. Pharmacoepidemiology and therapeutic risk management. Cincinnati: Harvey Whitney; 2008. p. 239–72.
Wang SV, Patterson OV, Gagne JJ, Brown JS, Ball R, Jonsson P, et al. Transparent reporting on research using unstructured electronic health record data to generate ‘real world’ evidence of comparative effectiveness and safety. Drug Saf. 2019;42(11):1297–309.
pubmed: 31452075
Torcel-Pagnon L, Bauchau V, Mahy P, Htar MTT, van der Sande M, Mahe C, et al. Guidance for the governance of public-private collaborations in vaccine post-marketing settings in Europe. Vaccine. 2019;37(25):3278–89.
pubmed: 31072735
Candore G, Juhlin K, Manlik K, Thakrar B, Quarcoo N, Seabroke S, et al. Comparison of statistical signal detection methods within and across spontaneous reporting databases. Drug Saf. 2015;38(6):577–87.
pubmed: 25899605
Platt R, Brown JS, Robb M, McClellan M, Ball R, Nguyen MD, et al. The FDA Sentinel initiative: an evolving national resource. N Engl J Med. 2018;379(22):2091–3.
pubmed: 30485777
Tsintis P, La Mache E. CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications. Drug Saf. 2004;27(8):509–17.
pubmed: 15154824
Duke Margolis Center for Health Policy. Implementation of signal detection capabilities in the Sentinel system: a discussion guide. 2018. https://healthpolicy.duke.edu/events/implementation-signal-detection-capabilities-sentinel-system . Accessed 21 Sept 2020.
Almenoff J, Tonning JM, Gould AL, Szarfman A, Hauben M, Ouellet-Hellstrom R, et al. Perspectives on the use of data mining in pharmaco-vigilance. Drug Saf. 2005;28(11):981–1007.
pubmed: 16231953
Califf RM. Introducing IMEDS, a public-private resource for evidence generation. FDA Voice 2017. https://www.focr.org/news/fda-voice-introducing-imeds-public-private-resource-evidence-generation . Accessed 21 Sept 2020.
Danysz K, Cicirello S, Mingle E, Assuncao B, Tetarenko N, Mockute R, et al. Artificial intelligence and the future of the drug safety professional. Drug Saf. 2019;42(4):491–7.
pubmed: 30343417
Sobel RE, Bate A, Marshall J, Haynes K, Selvam N, Nair V, et al. Do FDA label changes work? Assessment of the 2010 class label change for proton pump inhibitors using the Sentinel system’s analytic tools. Pharmacoepidemiol Drug Saf. 2018;27(3):332–9.
pubmed: 29392851
Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109–17.
pubmed: 10082069
Pissadaki E, Abrami A, Heisig S, Bilal E, Cavallo M, Wacnik P, et al. Decomposition of complex movements into primitives for Parkinson’s disease assessment. IBM J Res Dev. 2018;62(1):5:1–11.
Curtis LH, Weiner MG, Boudreau DM, Cooper WO, Daniel GW, Nair VP, et al. Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf. 2012;21(Suppl. 1):23–31.
pubmed: 22262590
Bate A, Hornbuckle K, Juhaeri J, Motsko SP, Reynolds RF. Hypothesis-free signal detection in healthcare databases: finding its value for pharmacovigilance. Ther Adv Drug Saf. 2019;10:2042098619864744. https://doi.org/10.1177/2042098619864744
doi: 10.1177/2042098619864744
pubmed: 31428307
pmcid: 6683315
Arlett P, Straus S, Rasi G. Pharmacovigilance 2030: invited commentary for the January 2020 “Futures” edition of Clinical Pharmacology and Therapeutics. Clin Pharmacol Ther. 2020;107(1):89–91.
pubmed: 31758540
Leape LL, Berwick DM. Five years after To Err Is Human: what have we learned? JAMA. 2005;293(19):2384–90.
pubmed: 15900009